Lionel Lim, PhD

Excited to share the latest feature in our "Partnering Spotlight" series, where we share some of the connections we are building to foster scientific innovation in healthcare. In this edition, our very own Neha Kaushal sits down with Daniel Anderson, Professor of Chemical Engineering at MIT, to discuss the potential of innovative #mRNA applications in vaccines and novel treatments for genetic diseases. Check out the video to learn more about our collaboration! https://lnkd.in/eHwpyjeY #vaccines #immunoscience

40

1 Comment

Have you seen the latest issue of the Journal of the National Comprehensive Cancer Network® (NCCN®)? There is a must-read article on research conducted by some of our brilliant team at Evidera!

14

What an interesting read on the shift from traditional patient recruitment methods in rare disease! Learn more about how to optimize patient-driven site engagement in my team member’s blog: https://bit.ly/4eHoBn4

3

How can sponsors prioritize diversity and inclusion of underrepresented populations in clinical trials and adhere to new guidelines from the U.S. Food and Drug Administration? Learn about strategies and recommendations for success in our latest publication: https://lnkd.in/egiDZtEg #ClinicalTrialInclusion #ClinicalTrialDiversity #ClinicalTrials

4

𝗠𝗮𝘀𝘁𝗲𝗿𝗶𝗻𝗴 𝗔𝗰𝗰𝘂𝘀𝗮𝘁𝗶𝗼𝗻 𝗔𝘂𝗱𝗶𝘁: 𝗔 𝗦𝗸𝗶𝗹𝗹 𝗳𝗼𝗿 𝗠𝗦𝗟𝘀 𝗮𝗻𝗱 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 Thanks to all of my fellow future leaders in the Aspire MSL program for sharing their insights yesterday. Learning together is how we lead better tomorrow. Engaging with KOLs requires more than just scientific knowledge, it demands empathy, understanding, and the ability to anticipate their concerns (also their concerns regarding your role as an MSL). During our recent Aspire MSL Book Club discussion, Matthew de Gannes, PhD , John Brannon, PhD and myself with other fellow members explored the concept of 𝗔𝗰𝗰𝘂𝘀𝗮𝘁𝗶𝗼𝗻 𝗔𝘂𝗱𝗶𝘁, a negotiation technique that involves addressing potential objections before they arise. In Medical Affairs, this skill can transform interactions with KOLs. By acknowledging unspoken concerns upfront, we can demonstrate that we truly understand their perspective and priorities, leading the way for meaningful discussions. This concept has profound implications for MSLs who often navigate complex scientific conversations. It's not just about sharing data… it is about building relationships based on mutual respect and understanding. Will always be curious now on how Accusation Audit can refine an approach to KOLs as an MSL or in other professional roles! Sarah Snyder Patrina Pellett, PhD MSL Mastery #LeadershipThroughLearning #AspireMSL #MedicalAffairs #NegotiationSkills

27

9 Comments

Oncology clinical trials are crucial for advancing cancer treatment and can help patients get access to cutting-edge therapies. Yet, the latest data show that the clinical trial enrollment rate for patients with cancer in the U.S. is just 7%. At Private Health Management, we understand the clinical and scientific complexity of identifying and prioritizing appropriate trials, as well as other barriers to access. In PHM’s new whitepaper, “The Importance of Clinical Trials in Cancer Care,” my colleagues, Natalya Gertsik, PhD, Tommy Axford, and I discuss how PHM’s approach to clinical trials can help to ensure access for all patients and present an analysis of clinical trial enrollment for our cancer patients over the last decade. Remarkably, the enrollment rate for PHM patients with cancer is 25% — nearly four times the rate of the general population. Patients across all cancer stages and over 20 cancer types enrolled in trials, demonstrating PHM’s commitment to ensuring access for all patients, even when few trials are available. By identifying suitable trials, supporting logistical needs of providers and patients, and educating patients about clinical trials, PHM helps overcome obstacles surrounding clinical trial access. Learn more here: https://lnkd.in/gz-3gaVP #clinicaltrials #employeehealth #cancer #oncology #healthequity #clinicalresearch #cancercare #employerbenefits #employerhealthplans

8

Using #geneticengineering in decentralized trials adds complications to IRB risk evaluations and overall participant safety efforts. Learn ways to approach these challenges in our September 17 webinar:

6

𝗥𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗼𝗻 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 𝗶𝗻 𝗛𝗲𝗽𝗮𝘁𝗼𝗹𝗼𝗴𝘆, 𝗚𝗮𝘀𝘁𝗿𝗼𝗲𝗻𝘁𝗲𝗿𝗼𝗹𝗼𝗴𝘆 & 𝗚𝗜 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 As Thanksgiving approaches, I find myself reflecting on the incredible journey of scientific discovery and collaboration in 𝘏𝘦𝘱𝘢𝘵𝘰𝘭𝘰𝘨𝘺 𝘢𝘯𝘥 𝘎𝘢𝘴𝘵𝘳𝘰𝘦𝘯𝘵𝘦𝘳𝘰𝘭𝘰𝘨𝘺 TA. It's a privilege to have been part of this evolving narrative, alongside brilliant KOLs and the transformative innovations that took place in Preventive Medicine, Screening, and Drug Development. It all began with the landmark paper by El-Serag and Mason in 1999 in 𝘕𝘦𝘸 𝘌𝘯𝘨𝘭𝘢𝘯𝘥 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘰𝘧 𝘔𝘦𝘥𝘪𝘤𝘪𝘯𝘦, which first highlighted the increasing incidence of hepatocellular carcinoma (HCC). Inspired by their work, I published my own study in the 𝘉𝘳𝘪𝘵𝘪𝘴𝘩 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘰𝘧 𝘊𝘢𝘯𝘤𝘦𝘳, analyzing global trends in HCC. Years later, I had the honor of co-authoring paper with the same renowned KOL, showing that HCC trends are, in fact, on the decline…. a significant milestone published in 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘎𝘢𝘴𝘵𝘳𝘰𝘦𝘯𝘵𝘦𝘳𝘰𝘭𝘰𝘨𝘺 𝘢𝘯𝘥 𝘏𝘦𝘱𝘢𝘵𝘰𝘭𝘰𝘨𝘺. This journey reminds me of the impact of cross-discipline collaborations in improving patient outcomes. I am deeply grateful to these exceptional KOLs, and industry leaders who make these advances possible. This Thanksgiving, I am thankful for the opportunity to contribute to this meaningful work and for the collective efforts that drive us closer to a healthier future in the U.S. #Hepatology #Gastroenterology #Thanksgiving #Collaboration #PreventiveMedicine #Innovation #MSL #MedicalAffairs #Gratitude #MedicalScienceLiaison

11

Important oncology news of the week: ✖ BMS $BMY pulling out of its collaboration with Agenus $AGEN to develop the AGEN1777 bispecific is another hit for the troubled TIGIT class. https://lnkd.in/ejdvSmbK 💊 Some good data from Boehringer in CRC and NSCLC G12C-mutant xenografts showing that combining the KRASi adagrasib with the SOSi BI-3406 results in much better anti-tumor activity. https://lnkd.in/eJmi64iy 💰 Merck $MRK and Daiichi Sankyo join forces to co-develop the DLL-3 targeting tri-specific antibody MK-6070 going mostly after small-cell lung cancer. Daiichi paid $170 million upfront for the Phase I/II asset https://lnkd.in/eVugSzUp ↘ Another failure for Ultimovacs results in stock price drop and forces the company to downsize. The combination of its cancer vaccines UV1 for head & neck cancer in combination with Keytruda failed to show additional synergy in the Phase II FOCUS study. https://lnkd.in/edCBRfQq ☑ Servier's Voranigo (vorasidenib) becomes the first FDA approved medicine for IDH-mutant Grade 2 astrocytoma or oligodendroglioma in over 20 years. The approval was based on the Phase III INDIGO study where Voranigo led to 27.7 mos mPFS vs 11.1 for placebo. https://lnkd.in/eym3n9FY ↘ Exelixis' $EXEL Cabometyx (cabozantinib) + Roche's Tecentriq (atezolizumab) failed to provide an OS benefit in mCRPC compared to 2nd novel hormonal therapy in the final analysis of the CONTACT-02 Phase III trial. Despite this, Exelixis plans to submit an sNDA regardless in a risky move where rejection is more likely. https://lnkd.in/emK4Sw9m ↖ Sanofi's $SAN PFS wing for the quadruplet Sarclisa + RVd regimen in transplant-eligible MM make a label expansion in the 1L almost certain, but will only complicate the treatment selection further without a head-to-head comparison with Darzalex. https://lnkd.in/eaVVavMG

7

Our team is proud to present our most recent publication: 👉 For patients with metastatic colorectal carcinoma, limited RAS pathway testing is standard of care for detection of primary resistance to anti-EGFR mAb therapy. 👉 We empirically evaluate the outcomes associated with a broader set of alterations that would biologically anticipate resistance (ERBB2, RTK, and RAS/PI3K) and found that empirical outcomes associated with these broader alterations similarly associates with limited clinical benefit from anti-EGFR therapy. 👉 Evaluating post-EGFR therapy specimens, we observe a greater prevalence in these alterations as well, temporally consistent with being resistance alterations. 👉 Because these alterations are not included in standard PCR panels, the results suggest greater utility for NGS testing at baseline for clinical decisions around anti-EGFR vs. anti-VEGF use. Ryon Graf, PhD, Matthew J. Emmett, MD, PhD, Samuel Klempner, Samantha Morley, Hanna Tukachinsky, and Alexa Schrock, PhD

69

Hot off the press!!! The link below will take you to my new article with access for a limited amount of time! Learn about payer perspectives on genomic testing and let me know what you think. My lessons learned are in the comments.... #genetics #genomics #geneticcounseling #healthpolicy #genechat #geneticcounselor #ELSI Hadley Smith Laura Rebek, MS, CGC https://lnkd.in/gfWFPH_6

67

4 Comments

Great day 1 at the #DIA #RWE24 meeting. Key themes today - Novel approaches and considerations for integrating RWD earlier - during clinical trial development Many new regulatory guidances to guide RWD for RWE Clinical Trial Diversity- Look forward to Day 2- #RTIHealthSolutions

17

#innovationtakesallofus Learn more at ventures.abbvie.com! For #preclinical #investment opportunities in AbbVie's strategic areas of interest, please email our #Ventures team with a concise description of the investment opportunity and accompanying non-confidential supporting materials at [email protected]!

24

Exciting updates from Bristol Myers Squibb on #mezigdomide (#CC92480) in combination with tazemetostat and dexamethasone for multiple myeloma! #Mezigdomide, a potent #CELMoD under investigation, has shown promising preclinical results, being significantly more potent than #iberdomide and other #IMiDs. In the CA057-003 trial (#NCT05372354), 13 patients who had undergone a median of 5 prior lines of therapy received #mezigdomide, #tazemetostat, and #dexamethasone. The overall response rate (ORR) was 53.8%, with higher mezigdomide doses yielding an ORR of 71.4%. The combination demonstrated a manageable safety profile, with grade 3/4 TEAEs occurring in 69.2% of patients. Notably, mezigdomide rapidly degrades Ikaros and Aiolos proteins, inducing apoptosis in multiple myeloma cells and stimulating the immune system. The future of CELMoDs like mezigdomide looks promising as they continue to show high synergy with traditional partners and advanced treatments. Get detailed analysis of the abstract here @ https://lnkd.in/eq2-MY47 Stay tuned for more updates! #MultipleMyeloma #ClinicalTrials #Mezigdomide #BMS #CancerResearch #CELMoDs #healthcare #business #clinicalstudies #clinicaltrials #results #phases #top #abstracts #myeloma #oncology #pharmacautical #hematology

12

CAR T cells have proven successful in clinical trials for blood cancers, and researchers are eager to apply the technology to other types of cancers and diseases. If your R&D strategy is leading you toward leveraging CAR T, you need this new white paper:

10

⚔ Battle of the anti-#FcRNs in myasthenia gravis... 📑 Johnson & Johnson touts its recent nipocalimab PIII data showcased at the #EAN: European Academy of Neurology Conference, possibly competitively positioned well vs. argenx's #Vyvgart. ⏩ Forward looking: 👥 To leverage efficacy as a differentiator; across a range of antibody-positive gMG patients (i.e., MuSK+, anti-LRP4+, and anti-AChR+) 🗓 Regulatory filing est. by EOY #gMG #GeneralizedMyasteniaGravis #Clinical #MedicalAffairs #Nipocalimab #ActivitiesOfDailyLiving #Autoimmune #Neurodegenerative #Pharma #Healthcare

2

To accelerate the development of the next generation of advanced cancer therapies, we can use multi-omics approaches to better understand the disease and identify the most appropriate therapeutic targets.    In our article, showcased at #AACR and published in April’s Cancer Discovery, my AstraZeneca colleagues @Richard Goodwin @Jorge Reis-Filho, @Simon Barry and I discuss the deployment of platforms that generate increasingly complex data, and consider how to translate these into practical and scalable applications.    Read the article here: https://lnkd.in/efh_g7EB   #Spatialomics #PrecisionMedicine #Multiomics 

95

3 Comments